Core Insights - Philips reported a Q4 2025 sales of €5.097 billion, a 1% year-over-year increase, with adjusted EBITA of €770 million and an EBITA margin of 15.1% [1][2] - For the full year 2025, sales totaled €17.834 billion (approximately ¥146.2 billion), a 1% decline from the previous year, but adjusted EBITA increased to €2.195 billion, with an EBITA margin of 12.3% [1][2] - Despite macroeconomic uncertainties, Philips demonstrated strong performance with improved gross margins and stable cash flow, while outlining financial targets for 2026-2028 [1][8] Financial Performance - Q4 2025 nominal sales growth was 1%, while comparable sales growth reached 7% [2] - Income from operations in Q4 2025 was €540 million, representing 11% of sales, compared to 4% in Q4 2024 [2] - Net income for Q4 2025 was €397 million, a significant recovery from a loss of €333 million in Q4 2024 [2] Business Segment Performance 1. **Diagnosis & Treatment** - Q4 2025 sales were €2.403 billion, a 2% decline, but comparable sales growth was 4% [3][4] - EBITA for this segment was €243 million, with an EBITA margin of 10.1% [3] 2. **Connected Care** - Q4 2025 sales were €1.422 billion, flat year-over-year, with a comparable sales growth of 7% [5][11] - Adjusted EBITA increased to €235 million, with an EBITA margin of 16.5% [5] 3. **Personal Health** - Q4 2025 sales reached €1.118 billion, a 9% increase, with comparable sales growth of 14% [6][7] - EBITA margin improved to 22.7%, driven by innovative product launches [6] Financial Outlook and Goals - Philips set financial targets for 2026, expecting comparable sales growth of 3% to 4.5% and an adjusted EBITA margin of 12.5% to 13.0% [8] - Free cash flow is projected to be between €1.3 billion and €1.5 billion [8] Strategic Developments - Philips continues to enhance its innovation-driven strategy through new technology releases and strategic acquisitions [9] - The company showcased several industry-leading innovations at the RSNA 2025, including the world's first helium-free 3.0T MRI system and an AI-driven spectral CT system [12][14] - A strategic acquisition of SpectraWAVE, Inc. aims to strengthen Philips' position in the coronary intervention market [15] - Philips entered a five-year strategic partnership with AdventHealth to upgrade patient monitoring equipment across its hospital network [16]